title: Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma.
abstract: We reviewed the medical records of 42 patients with cutaneous melanoma metastatic to the liver who underwent hepatic artery chemoembolization (HACE) at our institution. HACE resulted in radiologic response (38.9%) or disease stabilization (47.2%) in most patients. The median overall survival (OS) and time to progression (TTP) of liver disease were 7.7 and 6 months, respectively. Patient's age, lactate dehydrogenase (LDH) levels, type of treatment, number of extrahepatic metastatic sites, and response to therapy were found to be significant predictors of OS after HACE. Prolonged survival was seen in patients who responded to HACE (p = .034).
authors.affiliation: Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Judy
authors.initials: J
authors.lastname: Ahrar
authors.forename: Sanjay
authors.initials: S
authors.lastname: Gupta
authors.forename: Joe
authors.initials: J
authors.lastname: Ensor
authors.forename: Kamran
authors.initials: K
authors.lastname: Ahrar
authors.forename: David C
authors.initials: DC
authors.lastname: Madoff
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Wallace
authors.forename: Ravi
authors.initials: R
authors.lastname: Murthy
authors.forename: Alda
authors.initials: A
authors.lastname: Tam
authors.forename: Patrick
authors.initials: P
authors.lastname: Hwu
authors.forename: Agop Y
authors.initials: AY
authors.lastname: Bedikian
mesh_terms: D016461:Chemoembolization, Therapeutic / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008875:Middle Aged; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology*; D013781:Texas; D013997:Time Factors; D016896:Treatment Outcome